PharmStar Pharmaceuticals Names Dr. James Carlson to Its Board of Directors and as Chairman of the Medical Advisory Board
October 24 2011 - 9:20AM
Marketwired
PharmStar Pharmaceuticals, Inc. (PINKSHEETS: PHAR) (the "Company")
announced today that Dr. James Carlson has accepted a position on
the Board of Directors for the Company, and will also serve as the
Chairman for the Medical Advisory Board.
Dr. Carlson received a Bachelor of Science degree in
Biochemistry and Cellular Physiology from Cornell University. He
additionally received a Doctorate of Medicine degree from the New
York College of Osteopathic Medicine in Old Westbury, New York. Dr.
Carlson was the chief resident at Delaware Valley Medical Center in
Langhorne, Pennsylvania, and later obtained a Master's of Business,
with an emphasis on Healthcare Economics and Physician Practice
Management from Regis University in Denver, Colorado. He also holds
a Juris Doctorate in Law, with an emphasis in Healthcare law from
Concord University School of Law, located in Los Angeles,
California. Dr. Carlson's website can be found at:
www.drjamescarlson.com
Dr. Carlson is the author of "Genocide: How Your Doctor's
Dietary Ignorance Will Kill You," a controversial book detailing
the shortcomings of the medical community in the United States
while promoting a much healthier diet. He is the host of "Ultimate
Wellness with Dr. James Carlson," a radio and video commentary
program promoting good dietary practices and commenting on the
shortcomings of the medical community. This program can be viewed
on his YouTube channel, DreamweaverHouse.
Dr. Carlson stated, "I am honored to be working with PharmStar
and bringing this important technology to market. By eliminating
acid and sodium with Aquaprin, Howard has eliminated everything
that is wrong with the way we take aspirin. It's an unbelievable
product, and I can't wait to get the Medical Advisory Board fired
up and educating the medical community and the rest of the world
about this superior pain reliever."
CEO Howard Phykitt commented, "What an honor it is to announce
Dr. Carlson as a member of the Company's Board of Directors. He is
a physician, a businessman and a Health Care attorney, and is
passionate about his work. He uses his unique talents to explain
common sense ideas about diets and wellness programs, and will
bring a lot of energy to the Company. We are proud he has come
aboard."
Dr. Carlson will be speaking about and promoting Aquaprin
through his YouTube channel video productions, and whenever he is
speaking directly to the medical community.
About PharmStar Pharmaceuticals, Inc.
PharmStar Pharmaceuticals, Inc. ("PharmStar") is a U.S.-based drug
development, manufacturing and marketing company and the innovator
of the FDA-approved liquid pain reliever, Aquaprin™. In development
since 1993 with over $3 million invested to-date, Aquaprin™ is a
liquid derivative of aspirin, and is now ready for
commercialization. Aquaprin™'s unique, multiple patent-pending
formulas are designed to dissolve nearly instantly in just 1.5
ounces or more of water. This enables the product to be absorbed
into the bloodstream up to 10 times faster than traditional OTC
pain relievers, and with little to no stomach upset.
PharmStar initially plans to sell Aquaprin™ directly to nursing
homes, outpatient and health care clinics, emergency units of
hospitals nationwide, as well as retail distribution in selected
local markets and third-party websites to be announced. All package
engineering, product stability; shelf life testing and quality
control research has been completed. PharmStar's headquarters are
located in Wilson, NC.
Forward-Looking Statements Disclosure This press release
includes "forward-looking statements" within the meaning of the
federal securities laws, commonly identified by such terms as
"believes," "will," "looking ahead," "anticipates," "estimates" and
other terms with similar meaning. Although the Company believes
that the assumptions upon which its forward-looking statements are
based are reasonable, it can give no assurance that these
assumptions will prove to be correct. Important factors that could
cause actual results to differ materially from the Company's
projections and expectations are disclosed in the Company's filings
with the Securities and Exchange Commission. All forward-looking
statements in this press release are expressly qualified by such
cautionary statements and by reference to the underlying
assumptions.
Contact: PharmStar Pharmaceuticals, Inc. 919-794-7000 (During
message, press 5) info@pharmstarinc.com www.pharmstarinc.com
Investor Contact: investors@pharmstarinc.com